Bristol Myers Squibb Co. BMY, +2.01% announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB, +9.37% in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers will pay$62.50 in cash for each RayzeBio share outstanding, which represents a premium of 104.4% over Friday’s closing price of $30.57. RayzeBio’s stock was halted for new until 7:30 a.m. Eastern and Bristol Myers’ stock tacked on 0.2% in premarket trading. “This transaction enhances our incre ...